Q-omics provides the consensus-scored SCML2P1 profile across patient tissues and cancer cell-line models. SCML2P1 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, SCML2P1 is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, SCML2P1 RNA expression shows 6,967 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KICH, HNSC, and TGCT as cancer lineages where SCML2P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SCML2P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SCML2P1 survival associations across molecular data types. SCML2P1 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SCML2P1 RNA expression–survival associations across cancer types. High SCML2P1 expression shows unfavorable associations in KICH, BRCA, GBM and LIHC, but favorable associations in HNSC and ESCA. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for SCML2P1 RNA expression.
This table summarizes SCML2P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for SCML2P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SCML2P1 shows higher tumor expression in HNSC, LUSC, BRCA, PRAD and STAD. The HNSC box plot shows higher SCML2P1 RNA expression in tumor versus normal tissue (log2 FC = +0.024, t-test p = .004).
This table shows molecular features associated with SCML2P1 in patient tissues and cancer cell lines. In patient samples, SCML2P1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
